Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GreeceBack to Greece

Clinical trials in Thessaloniki – page 42

685 clinical trials in Thessaloniki, Greece across 7 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Thessaloniki at a glance
685
clinical trials
  • Research sites7
Type of trial
Recruitment status
Quick filters

685 trials in Thessaloniki

Open in trial search

Non-small cell lung cancer metastatic

Not recruiting

Study Comparing MK-2870 with Chemotherapy (Docetaxel or Pemetrexed) for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Mutations

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Merck Sharp & Dohme LLC

Bladder transitional cell carcinoma

Not recruiting

Study on Atezolizumab for Patients with High-Risk Muscle-Invasive Bladder Cancer with Positive ctDNA After Surgery

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Safety and Effectiveness of Ocrelizumab vs. Fingolimod for Children and Adolescents with Relapsing-Remitting Multiple Sclerosis

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years
  • Substances:DIMENHYDRINATE
  • Sponsor:F. Hoffmann-La Roche AG

Chronic graft versus host disease

Not recruiting

Study of Belumosudil and Prednisone for Patients Aged 12 and Older with Newly Diagnosed Chronic Graft Versus Host Disease

Registered drug
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Non-small cell lung cancer+2

Not recruiting

Study of Niraparib and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Glaxosmithkline Research & Development Limited

Plasma cell myeloma

Not recruiting

Study Comparing Talquetamab, Pomalidomide, and Teclistamab for Patients with Relapsed or Refractory Myeloma After 1 to 4 Prior Treatments

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Janssen Cilag International

Plasma cell myeloma

Not recruiting

Study of Isatuximab, Lenalidomide, and Dexamethasone for Patients with High-Risk Smoldering Multiple Myeloma

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Severe myoclonic epilepsy of infancy+1

Not recruiting

Study on Long-Term Safety of Soticlestat for Patients with Dravet or Lennox-Gastaut Syndromes

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Soticlestat
  • Sponsor:Takeda Development Center Americas Inc.

Non-small cell lung cancer

Not recruiting

Study Comparing Entrectinib and Crizotinib for Patients with Advanced Non-Small Cell Lung Cancer with ROS1 Gene Changes, With or Without Brain Metastases

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:F. Hoffmann-La Roche AG

Urinary tract infection

Not recruiting

Title: Comparison of oral tebipenem pivoxil versus intravenous imipenem-cilastatin in adults with complicated urinary tract infection or acute pyelonephritis

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Cilastatin
  • Sponsor:Spero Therapeutics Inc.

Neoplasm

Not recruiting

Study on the Safety of Tiragolumab and Atezolizumab for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Gastric cancer

Not recruiting

Study of Bemarituzumab and Chemotherapy for Patients with Advanced Stomach or Gastroesophageal Cancer with FGFR2b Overexpression

Registered drug
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years
  • Substances:Bemarituzumab
  • Sponsor:Amgen Inc.

Other cities in Greece

The busiest research cities in the country

All 50 cities in Greece

Clinical research in Thessaloniki

What the registry says about research in the country

01 Oncology Research

Groundbreaking studies focusing on head and neck squamous cell carcinoma, multiple myeloma, and advanced malignancies. Research includes innovative treatments for bladder cancer and gastrointestinal tumors.

  • Advanced cancer therapies
  • Combination treatment approaches
  • Novel therapeutic agents

Investigations emphasize improving survival outcomes and treatment efficacy.

02 Autoimmune Conditions

Clinical trials addressing various autoimmune disorders including cutaneous lupus erythematosus, systemic sclerosis, and Sjögren's Syndrome. Studies evaluate new biologics and targeted therapies.

  • Skin manifestations
  • Systemic complications
  • Immune system modulation

Research focuses on developing more effective treatments with improved safety profiles.

03 Metabolic Disorders

Comprehensive studies on Type 1 Diabetes and obesity, investigating novel therapeutic approaches. Trials examine treatments for weight management and glycemic control.

  • Blood sugar management
  • Weight control interventions
  • Cardiovascular outcomes

Research aims to improve patient outcomes through innovative treatment combinations.

Back to GreeceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.